7 March 2026
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
9 February 2026
3 February 2026
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.
19 January 2026
Aspen Pharmacare is lining up a generic semaglutide launch in Canada, promising big discounts, and widening GLP-1 access.
14 January 2026
GLP-1 weight loss drugs like Mounjaro and Wegovy are transforming obesity treatment in SA amid rising health concerns and systemic barriers.
6 January 2026
NEMLC begins a GLP-1 medicines review to assess affordability and potential inclusion in the public health sector for diabetes and obesity
6 January 2026
Illegal weight loss injections are flooding the local market as high costs and obesity rates drive a dangerous market for GLP-1 agonists.
15 October 2025
Understand the impact of the surge in illicit medicines on public health in South Africa and the measures being taken to protect patients.
11 September 2025
26 August 2025
Find out how GLP-1 drugs like Ozempic and Wegovy can lower cancer risk while aiding in weight loss and diabetes control.
8 November 2024
ObesityWeek 2024 attracted unprecedented attention from Wall Street, highlighting obesity treatment's booming pharmaceutical industry.